.

Media

23 June 2021

“New vaccine should protect longer” – BZ Basel is reporting about RocketVax’s SARS-CoV-2 vaccine

The University Hospital Basel (USB), the University of Basel, and the Swiss Tropical and Public Health Institute (Swiss TPH) are entering into a research collaboration with the startup company RocketVax. The goal is to develop a next-generation vaccine against Covid-19 that will provide better protection against viral mutants and elicit a longer-term immune response. The […]

22 June 2021

BaZ: “Basel government approves one million for coronavirus vaccine”

“The Basel government is getting involved in the development of another vaccine against Covid-19. The government approved a CHF 1 million grant from the local development fund to support the preclinical development of a vaccine from the Basel-based start-up RocketVax. RocketVax, founded in the summer of 2020 and headquartered in Basel, is a subsidiary of […]

18 June 2021

BZ Basel: On behalf of the Basel start-up RocketVax, Prof. Dr. Thomas Klimkait is developing a new type of coronavirus vaccine

Basel University Hospital, the University of Basel, and the Swiss Tropical and Public Health Institute have agreed to collaborate with the company RocketVax and jointly advance research to develop a novel vaccine against the SARS-CoV-2 coronavirus. BZ Basel published an article on Prof. Dr. Thomas Klimkait, our Project Leader in Vaccine Design and Preclinical Virology. […]

28 May 2021

Prof. Dr. Manuel Battegay, Head of the Department of Infectious Diseases & Hospital Epidemiology at University Hospital Basel, spoke about the current Coronavirus situation

Prof. Dr. Manuel Battegay is Head of the Department of Infectious Diseases & Hospital Epidemiology at University Hospital Basel. In his interview for the University of Basel, he gave his expert’s opinion on some actual questions related to the COVID-19 pandemic and coronavirus vaccines such as:   How can we prevent severe cases of coronavirus infection?   Should healthy […]

22 April 2021

CEO of RocketVax, Dr. Vladimir Cmiljanovic, spoke to Watson about the development of a next-generation SARS-CoV-2 vaccine, RVX-13

“There is light at the end of the tunnel. Progress is being made in vaccines against SARS-CoV-2, if somewhat slowly, particularly in Switzerland. They promise a return to normality, though they are not without setbacks. The vector vaccines developed by AstraZeneca and Johnson & Johnson are under fire following cases of thrombosis in younger women. […]